Genome-wide association studies (GWAS) have revealed important biological insights into
complex diseases, which are broadly expected to lead to the identification of new drug …

Genome-wide association studies have identified hundreds of robust genetic associations
underlying psychiatric disorders and provided important biological insights into disease …

Psychotropic medication efficacy and tolerability are critical treatment issues faced by
individuals with psychiatric disorders and their healthcare providers. For some people, it can …

Polygenic risk scores (PRS) have been successfully developed for the prediction of human
diseases and complex traits in the past years. For drug response prediction in randomized …

There is a long-standing interest in exploring the relationship between blood-based
biomarkers and psychiatric disorders, despite their causal role being difficult to resolve in …

Since the first polygenic risk score (PRS) in 2007, research in this area has progressed
significantly. The increasing number of SNPs that have been identified by large scale GWAS …

Genetically informed drug development and repurposing is an attractive prospect for
improving patient outcomes in psychiatry; however, the effectiveness of these endeavors is …

Drug repurposing has become an effective approach to drug discovery, as it offers a new
way to explore drugs. Based on the Science Citation Index Expanded (SCI-E) and Social …

Schizophrenia has a multifactorial etiology, involving a polygenic architecture. The potential
benefit of whole genome sequencing (WGS) in schizophrenia and other psychotic disorders …

Pneumonia remains one of the leading causes of death worldwide. In this study, we use
genome-wide meta-analysis of lifetime pneumonia diagnosis (N= 391,044) to identify four …